Drug Profile
Research programme: cancer and infectious disease therapeutics - Inhibikase Therapeutics
Alternative Names: Anti-bacterial AblKi; EGFRi HepC; IkT-004; IkT-014; IkT-041; IkT-061; IkT-064; PML SAR; Virus-similar particle vaccine; VSP vaccineLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Inhibikase Therapeutics
- Class Small molecules; Viral vaccines
- Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Raf kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diarrhoea; Hepatitis C; Polyomavirus infections; Respiratory tract infections; Viral infections
- Discontinued Influenza A virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Viral-infections in USA
- 04 Nov 2017 No recent reports of development identified for research development in Hepatitis-C in USA
- 04 Nov 2017 No recent reports of development identified for research development in Polyomavirus-infections in USA